A critical component of lowering the cardiovascular disease burden across the population is identification and aggressive treatment of high-risk individuals. The Adult Treatment Panel III of the Expert Panel of the National Cholesterol Education Program (1) has identified a group of risk factors associated with cardiovascular disease, including elevated low-density lipoprotein (LDL) cholesterol concentrations, cigarette smoking, hypertension, reduced high-density lipoprotein (HDL) cholesterol concentrations, family history of premature coronary heart disease, and older age. Current efforts have focused on determining whether additional diagnostic criteria could improve the accuracy of cardiovascular disease risk estimation (2) (3) (4) (5) . Measures of LDL subfractions have been suggested as a potential risk factor.
Many terms are used to describe the characteristics and distribution of LDL particles; these include LDL subclasses, particles, particle concentration, particle numbers, and various patterns. These terms describe separate, but sometimes overlapping, features of the LDL particle. To simplify matters, we use the generic term subfractions except when describing specific measurements. Despite this simplification, we are not suggesting that the disparate methods for analyzing LDL can be fully subsumed in a single concept. Numerous methods are used to measure or define LDL subfractions. Table 1 lists the principal methods used and the most commonly reported subfraction measures. Only a few of these disparate systems to estimate LDL subfractions are routinely available, and only from selected clinical laboratories.
If LDL subfractions are predictive of cardiovascular risk and are of incremental value when added to established cardiovascular risk factors, it remains to be determined whether the different characteristics of the LDL subfractions assessed by various methods would result in similar predictive abilities for estimating cardiovascular risk. Lipid researchers have proposed that small, dense LDL particles confer greater atherogenic risk than larger, less dense LDL particles (6, 7) . In vitro, small, dense LDL particles are more avidly taken up by macrophages than larger, less dense LDL particles; are more susceptible to oxidative modification, have a greater propensity for transport into the arterial subendothelial space; and have a greater binding potential to arterial wall proteoglycans (8, 9) .
The American Diabetes Association and the American College of Cardiology Foundation convened a panel of experts to develop a consensus position for patients with "cardiometabolic risk" (10) . They noted that limited data from cross-sectional and prospective studies suggest that LDL particle number may be a better discriminator of cardiometabolic risk than LDL cholesterol concentrations. They pointed out several limitations, including availability and accuracy of the method and consistency of the predictive power across ethnic groups, ages, and conditions that affect lipid metabolism. They concluded that it is yet to be determined whether treatment decisions would be improved if LDL subfraction measurements were added to the current risk factors used to estimate cardiovascular risk.
We sought to evaluate the association between LDL subfractions and incidence and progression of clinical cardiovascular disease. We focus primarily on the LDL subfraction tests that are available for routine use by clinical laboratories and are thus available to all U.S. clinicians and their patients. We also summarize the potential value of LDL subfraction tests used only in research laboratories. An earlier version of this systematic review was conducted as part of a Technology Assessment for the Centers for Medicare & Medicaid Services (11) .
METHODS

Data Sources and Searches
We conducted a comprehensive search of the scientific literature to identify relevant studies in MEDLINE (1950 Table 1 (available at www.annals.org) lists search terms for LDL, particle size or subfractions, and test methodologies. We limited the literature searches to humans and English-language publications. The searches were supplemented by screening reference lists of included studies and selected reviews and requesting more information from domain experts.
Study Selection
Three investigators screened all citations and retrieved articles for eligibility. We included studies of any prospective, longitudinal design that reported an association between any measure of LDL subfractions and either incident cardiovascular disease (cardiac, cerebrovascular, or peripheral vascular disease) or progression of disease severity (for example, coronary atherosclerosis) and had at least 10 adults per study group. Serum (or plasma) samples must have been obtained before determination of outcomes. We evaluated only clinical outcomes or measures of atherosclerosis on which clinical decisions are made (for example, minimum lumen diameter). We placed no further restrictions on study populations and included studies of people 
Commonly used tests to measure LDL subfractions
Nuclear magnetic resonance: Clinically available test using a mass spectrometer. Measures the signal from the aggregate number of terminal methyl groups in the lipid within the particle. The number of methyl groups is reflected in the amplitude of the methyl NMR signal. The amplitude of each lipoprotein particle signal serves as a measure of the concentration of that lipoprotein. The NMR data are converted into subfraction concentrations by using assumptions in proprietary software. Size and pattern of LDL can be derived through additional calculations. LipoPrint gel electrophoresis*: Clinically available test using a specific gel kit, equipment, and method for defining LDL subfractions. Relatively rapid system compared with most gel electrophoresis methods. Separates particles into 7 subfractions by size and to a lesser extent charge. Lipoprotein subfraction profiles can be classified into type A or B. Use of LipoPrint to determine particle sizes or LDL scores or any other form of classification is not recommended by the manufacturer of the kit but is routinely done by researchers. Berkeley HeartLab segmented gel electrophoresis*: Clinically available test using a specific gel kit together with a proprietary computer algorithm for calculating the number of particles in an LDL subfraction. Separates particles into 7 LDL subfractions (I, IIa, IIb, IIIa, IIIb, IVa, and IVb) on the basis of particle size and shape. Bench gel electrophoresis †: The principal method used in research laboratories to measure LDL subfractions. The LDL subfractions are separated by electrophoresis across a sodium dodecyl sulfate gradient gel. For the majority of specific gel electrophoresis methods, researchers create their own gels and apply nonstandardized techniques to separate the LDL subfractions. Different compounds are used to create the gels, although polyacrylamide is the most common. Different distributions of gel densities are used. Different approaches are used to define and determine the specific LDL subfractions. Ultracentrifugation †: Performed only in research laboratories by using a variety of instruments, specific methods, and definitions of LDL subfractions. The LDL subfractions are separated by ultracentrifugation on the basis of density. A variety of arbitrary density cut-points between subfractions has been reported.
with and without cardiovascular disease at baseline. No minimum follow-up duration was required.
Data Extraction
One of the three authors extracted data from each study, and at least 1 additional author reviewed and verified the extractions. Full data extraction, including quality assessment, was performed for studies that used specific methods or kits that are currently available to clinical laboratories (as opposed to research laboratories). From the best information available to us from the Centers for Medicare & Medicaid Services, the U.S. Food and Drug Administration, domain experts, the reviewed studies, internet searches, invited reviewers, and conversations with several laboratories, we limited the full analysis to nuclear magnetic resonance (NMR), 
Quality Assessment
We assessed the methodological quality of each fully extracted study on the basis of predefined criteria (12) . The primary data extractor determined the study quality, and at least 1 other extractor confirmed it. We used a 3-category grading system to denote the methodological quality of each study. Good-quality studies adhere most closely to the commonly held concepts of high quality, including clear descriptions of the population, setting, LDL subfraction measures, and analytic technique; appropriate measurement of outcomes; appropriate statistical analysis, including multivariable analysis adjusting for lipid measures; no obvious reporting omissions or errors; clear reporting of dropouts; and complete reporting of associations of interest for this systematic review. Fair-quality studies have some deficiencies, but these are unlikely to cause major bias. Poor-quality studies failed to adequately describe the measures, analyses, or results of interest or had substantial flaws in reporting or statistical analyses, such that major bias could not be excluded. The quality assessment was based specifically on the analysis of LDL subfractions and clinical cardiovascular outcomes, regardless of the primary analysis of interest to the original researchers.
Role of the Funding Source
The Agency for Healthcare Research and Quality participated in formulating the study questions but did not participate in the literature search; determination of study eligibility; data analysis or interpretation; or preparation, review, or approval of the manuscript for publication.
RESULTS
The literature searches yielded 6724 citations (Figure) , of which 476 were retrieved for further consideration for 
NMR-Measured LDL Subfractions
All 10 studies that examined the relationships between NMR-measured LDL subfractions and cardiovascular outcomes had their samples run by a common group of researchers at LipoScience (Raleigh, North Carolina) or its precursors. The studies included 2 prospective longitudinal studies and 8 nested case-control studies of cardiovascular treatment trials or large epidemiologic studies (Appendix Table 2 , available at www.annals.org). Nine studies (with 12 subgroup analyses) evaluated incident cardiovascular disease ( Table 2) , and 1 study evaluated severity of cardiovascular disease ( Table 2) . Two of the nested case-control studies fulfilled the criteria of good methodological quality; the other 8 studies were of fair methodological quality. The number of participants in these studies ranged from 118 to 3066 (median, 556). Many of the studies used different definitions of the LDL subfractions (Table 3). The studies evaluated heterogeneous populations, but most included primarily older men with a history of cardiovascular disease. Five studies (13, 14, 16, 18, 19) included healthy populations at baseline. The mean LDL cholesterol concentration across the studies ranged from 2.9 to 4. CAD ϭ coronary artery disease; CVD ϭ cardiovascular disease (including cerebrovascular and peripheral vascular disease); LDL ϭ low-density lipoprotein. * Statistical significance of mean LDL subfraction values in participants with vs. those without cardiovascular events. † Statistical significance of regression analysis (odds ratio, hazard ratio, or risk ratio); significant analyses per total analyses. ‡ Significant analyses per total analyses. § For statistically significant differences. 1 study (13) reported an association (in graphical terms) but did not report statistical significance. 1 study (16) implied, but did not report, a lack of a significant association in 1 analysis (men). ¶ Unclear whether the analysis was lipid-adjusted in 1 study (16) . ** Intracerebral hemorrhage.
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For the evaluation of incident cardiovascular disease risk (Tables 2 and 3) , 10 analyses evaluated LDL particle number (concentration in nmol/L), 8 evaluated LDL particle size, and 8 evaluated concentrations of different-sized LDL particles (generally small, medium, and large).
LDL Particle Number and Incidence of Cardiovascular Disease
Among the studies evaluating particle number, the 5 that adjusted for cholesterol concentrations (13) (14) (15) (16) 19) found associations between higher particle number and increased incidence of cardiovascular disease, although 1 of these studies (13) did not report whether this analysis was statistically significant. In addition, 1 study (16) reported lipid-adjusted analyses in women but not in men (suggesting that the lipid-adjusted analysis in men was not statistically significant). Three of these studies (14, 16, 19) divided participants into quartiles based on LDL particle number and found that those in the highest quartiles were at increased risk for cardiovascular events compared with those in the lowest quartile (2 studies also reported a statistically significant trend across quartiles [14, 19] ). The other 2 studies (13, 15) measured increased risk per 1-SD increase in LDL particle number. Two studies (13, 18) found statistically significant associations between higher LDL particle number (without adjustment for cholesterol concentrations) and cardiovascular events in 3 of 4 subgroup analyses. In 6 studies, 7 of 9 subgroup analyses found that participants who developed cardiovascular disease had higher LDL particle numbers at baseline. One of the 2 studies (20) that found no association evaluated intracerebral hemorrhage as an outcome; the other studies all evaluated atherosclerotic cardiovascular disease.
LDL Particle Size and Incidence of Cardiovascular Disease
Seven studies (with 8 subgroup analyses) (14 -17, 19 -21) evaluated LDL particle size. None of 4 lipid-adjusted analyses found an association with cardiovascular events. Among 3 studies with unadjusted analyses, 1 found no association (14) , 1 found that participants in the smallest quartile of LDL particle size had a statistically significantly higher risk for cardiovascular events (although it did not report the unit of analysis or whether the analysis was lipidadjusted) (16) , and the study of intracerebral hemorrhage (20) found a trend toward a greater risk with larger particles. In the 7 comparisons of mean baseline LDL particle size, 4 studies found statistically significantly smaller particles among persons with cardiovascular events, whereas 1 study found statistically significantly larger particles in those with intracerebral hemorrhage. However, the mean baseline LDL particle sizes were so similar that the clinical significance of this association is unclear; both means fell within the small LDL category ( Table 1) . The largest absolute difference in mean particle sizes was 206 versus 210 Å (21).
LDL Subfraction Concentration and Incidence of Cardiovascular Disease
Seven studies (with 8 subgroup analyses) (14 -17, 19 -21) evaluated small and large LDL particle concentrations as possible predictors of cardiovascular events. Neither study that performed lipid-adjusted analyses (15, 21) found a statistically significant association with either small or large LDL subfractions. Neither lipid-unadjusted analysis of large particles (17, 20) found an association. In an analysis that lacked information on whether lipid adjustment was done (16) , participants in the quartile with the highest concentration of the small LDL subfraction were at increased risk for incident coronary artery disease, but the same researchers found no association with cardiac death in a separate cohort (17) . Three of 7 analyses found that participants who developed cardiovascular disease had higher concentrations of small LDL particles at baseline. In contrast, the 2 (of 7) statistically significant analyses of mean baseline levels (14, 20) both found that higher concentrations of large LDL particles were associated with intracerebral hemorrhage or coronary artery disease.
LDL Subfractions and Severity of Cardiovascular Disease
One fair-quality study evaluated a measure of coronary artery lumen diameter ( Table 2 ). Rosenson and colleagues (22) reported an association between both smaller LDL particle size and concentration of small LDL particles (183 to 197 Å) and a decrease over time in minimum lumen diameter. The study reported adjusted odds ratios of 0.2 (95% CI, 0.1 to 0.9) for particle size (above vs. below median size) and 9.1 (CI, 2.1 to 39) for concentration of small LDL particles (above vs. below median concentration). Large particle (213 to 230 Å) concentration and LDL particle number were not associated with change in minimum lumen diameter.
All Methods of Measuring LDL Subfractions
Fourteen studies (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) used other methods to measure LDL subfractions (not universally available to clinicians). We extracted only basic data from these studies (Appendix Tables 3 and 4 , available at www.annals.org) and summarized them together with the fully extracted studies. Table 4 lists the number of studies, separate analyses, and participants included for all methods of measuring LDL subfractions (clinically available and other methods). The data are divided by the outcome type and the LDL subfraction measurement type (size, number, or pattern). We separately counted the results of analyses that were unadjusted or adjusted for cholesterol concentrations. The numbers of studies that reported statistically significant "positive," "negative," or nonsignificant associations are summarized. We also enumerated the studies that reported both unadjusted and adjusted analyses.
The designs of the additional studies were similar to those that used NMR or Berkeley HeartLab gel electrophoresis. They evaluated a wide range of populations, including persons with and without baseline cardiovascular disease, with various comorbid conditions and receiving a wide range of medications (although this was generally not explicitly described).
The majority of analyses (37 of 52) found that LDL subfraction size, number, and pattern were statistically significantly associated with cardiovascular outcomes in unadjusted analyses. For each measurement type, the majority of unadjusted analyses found an association with cardiovascular disease.
Compared with the 52 unadjusted analyses, there were only 26 lipid-adjusted analyses. The distribution of statistically significant and nonsignificant associations was more evenly split among the adjusted analyses; 12 of 26 such analyses found statistically significant adjusted associations with incident cardiovascular disease or progression. How- Of note, many of these adjusted analyses were reported without presenting the unadjusted analyses. To understand the impact of adjustment on the findings of statistically significant associations, we evaluated how findings changed within the 26 analyses that reported both unadjusted and lipid-adjusted analyses. Among the analyses that found a statistically significant unadjusted association between LDL subfractions and incident cardiovascular disease or progression, 9 of 20 became statistically nonsignificant after adjusting for lipid and other factors. An additional 6 analyses remained statistically nonsignificant regardless of adjustment. Overall, similar to the separately analyzed unadjusted and lipid-adjusted results, few size analyses remained statistically significant after adjustment (3 of 13), whereas most number and pattern analyses remained statistically significant after adjustment (8 of 13).
DISCUSSION
Many studies have evaluated the association between LDL subfractions and cardiovascular outcomes. However, relatively few of these were performed with 1 commonly used measurement method-NMR-and none with the other clinically available methods. In addition to the variety of measurement methods used among all of the studies and the large number of studies that included methods not in clinical use, the specific subfractions evaluated have been inconsistent. Even among the NMR studies, which mostly evaluated LDL particle number and particle size, different cut-points were used for the various LDL subfractions. Most of the studies were graded fair quality, on the basis of such factors as failure to fully adjust for other risk factors or inadequate descriptions of models used, incomplete reporting of the analyses of interest for this review, small sample size, or incomplete reporting of LDL subfraction test methodology. All of these issues create important limitations in evaluating the comparability of the studies and the applicability of the studies to the question of whether measurement of LDL subfractions is clinically valuable, in terms of helping clinicians and patients to assess both cardiovascular risk and potential need for treatment. Nevertheless, the studies generally found that LDL particle number (an NMR-specific measurement) was associated with incident cardiovascular disease, but LDL particle size and small LDL particle fraction were not as consistently associated with incident disease.
None of the studies reported adequate analyses to determine the relative or incremental value of LDL subfraction measurement as a predictor of cardiovascular disease compared with traditional risk factors (1) . No study compared LDL subfraction measurements with cardiovascular risk assessment technologies, by measuring the incremental increase in their diagnostic performance. Also, no study evaluated test performance (for example, sensitivity and specificity) of LDL subfractions to predict cardiovascular disease. Thus, even with evidence that higher LDL particle number may predict incident cardiovascular disease, evidence is lacking to support the clinical usefulness of adding the test to the traditional cardiovascular risk factors, including lipid and blood pressure measurements. This conclusion is consistent with that reached in the American Diabetes Association and the American College of Cardiology Foundation consensus statement (10) .
Publication bias against studies that found null or negative outcomes may be an important factor determining the available published evidence (37) . All of the articles on clinically available tests and most of the other articles reported data from secondary or post hoc analyses. It is likely that the positive secondary analyses were more often reported because negative results may be considered uninteresting and are thus less likely to be selected for journal publication or included in articles because of space limitations (38) . The review process had other limitations beyond the limitations of the evidence itself. We focused on the methods available to clinical laboratories for measuring LDL subfractions. This approach may have put undue emphasis on commercial entities and may have underappreciated unique features of other available tests; however, the generalizability of resource-and time-intensive methods used only by research laboratories is probably limited with respect to clinical practice. It is unclear how the financial interests of the manufacturers of the clinically available methodologies may have affected which sets of samples were analyzed, what analyses were performed, or what results were published. In addition, across studies, we could not adequately judge the nuances of the different methods on the basis of technical details (when reported). We therefore could not evaluate how these issues may have affected the differences in results among the studies. Nonetheless, except for potential publication bias, these issues may be of relatively minor importance compared with the large degree of heterogeneity in test methods and measures, populations evaluated, and outcomes assessed.
Current research has identified a potential association between LDL subfractions and cardiovascular disease (both heterogeneously defined), but the data to support its value as an independent risk factor for general clinical use are currently limited. Future research regarding the putative incremental utility of LDL subfractions to improve esti-mates of cardiovascular risk will need to focus on uniformly (and universally) defined measures of LDL subfractions. From a clinical perspective (as opposed to a laboratory perspective), it is most important that a given analytical technique can be consistently performed and standardized across laboratories. Thus, standardization of LDL subfractions measures across research and clinical laboratories is needed. Only when clinical laboratories are using the same analytic techniques as researchers can clinicians expect to understand the value of the LDL subfraction tests. Currently, at least 3 LDL subfraction measurement methods are available for clinical use, but the current studies are not adequate to compare their reliability or test performance (39, 40) .
The clinical utility of any new test (its value as a new predictor to evaluate cardiovascular risk) is of paramount importance. The observation of an association between risk factor and outcome alone, as was evaluated by the reviewed studies, is only a first step that must be confirmed by trials that attempt to modify the risk factor. This point is illustrated by the case of homocysteine: Strong observational data (41) suggested a positive association between plasma concentrations of homocysteine and cardiovascular outcomes, but randomized trials (42, 43) of treatments that successfully decreased homocysteine concentrations did not result in statistically significant benefit on cardiovascular end points or total mortality. Thus, even if LDL subfraction testing proves to be associated with cardiovascular outcomes, the tests will be of clinical value only if treatments based on the results of the LDL subfraction testing prove to be beneficial (44). 
